SAN DIEGO - Cue Health Inc. (NASDAQ:HLTH), a healthcare technology company, announced strategic leadership changes with Clint Sever, co-founder and Chief Product Officer, taking over as CEO, effective immediately. Sever steps into the role following the departure of Ayub Khattak, who will continue to serve on the Board of Directors.
In addition to the CEO transition, the Board has appointed two strategic advisors, Dr. Paul Brown, former President and CEO of Roche Molecular Diagnostics, and Dr. Lisa Danzig, former Global Head of Medical & Scientific Affairs at Grifols. Their expertise in diagnostics, healthcare regulations, and research and development is expected to provide guidance for Cue's future direction.
Cue has also initiated a comprehensive review of its business operations, aiming to refine the company's strategy and cost structure to better position itself for future growth.
The Board expressed gratitude to Khattak for his leadership and contributions, crediting him and Sever for building Cue's healthcare technology platform. The company remains focused on its vision of making diagnostic-enabled healthcare accessible to everyone, offering connected, fast, and accurate testing.
Sever, who has been responsible for product development and operations at Cue, holds over 60 patents and has a degree in retail and consumer science from the University of Arizona. His familiarity with Cue's operations is anticipated to enable a smooth transition into the CEO role.
This leadership change comes as Cue continues to innovate in the field of at-home and point-of-care diagnostic testing, including receiving FDA De Novo authorization for its COVID-19 test and Emergency Use Authorization for its molecular Mpox test.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.